Cimzia for Psoriasis: Efficacy, Safety, and Pregnancy

Cimzia (certolizumab pegol) is an anti-TNF biologic approved for moderate-to-severe plaque psoriasis that clears skin effectively in most patients, though it generally lands in the middle tier of today’s biologics for raw clearing power. What makes it genuinely distinct is its molecular structure, which lacks a component found in every other anti-TNF drug and gives it a meaningful advantage during pregnancy and breastfeeding. For people whose treatment decisions involve family planning or joint disease alongside skin symptoms, Cimzia occupies a niche that no other biologic quite fills.

What Makes Cimzia Structurally Different

Most anti-TNF biologics are full antibodies. Cimzia is not. It is a humanized fragment of an antibody (called a Fab’ fragment) that has been attached to polyethylene glycol, a polymer that extends the drug’s life in the body so it does not get cleared too quickly.¹ The critical missing piece is the Fc region, which is the tail end of a normal antibody that interacts with the immune system in ways beyond just blocking TNF. Other anti-TNF drugs like adalimumab and infliximab carry this Fc portion; Cimzia does not.² That structural difference has practical consequences. The Fc region is what allows antibodies to be actively transported across the placenta during pregnancy, so removing it changes the drug’s behavior in a way that matters for a specific group of patients.

How Well It Clears Psoriasis

Cimzia was tested in three large phase 3 trials for plaque psoriasis: CIMPASI-1, CIMPASI-2, and CIMPACT. Two doses were studied, 200 mg and 400 mg, both given every two weeks by injection. In the CIMPASI trials, by week 48, roughly 73% of patients on the 200 mg dose and about 84% on the 400 mg dose achieved at least a 75% improvement in their psoriasis severity score. The deeper clearance threshold of 90% improvement was reached by about 51% on the lower dose and 63% on the higher dose.³ Both doses significantly outperformed placebo at every measured time point.⁴

The CIMPACT trial added an active comparator, etanercept (Enbrel), which was the standard anti-TNF for psoriasis at the time. The higher Cimzia dose (400 mg) proved superior to etanercept, while the 200 mg dose was noninferior, meaning it performed at least as well.⁵ These are solid results, though etanercept is not the toughest benchmark anymore — newer drug classes have raised the bar considerably.

Durability Over Three Years

One legitimate concern with any biologic is whether it keeps working. The CIMPASI and CIMPACT trials followed patients into open-label extension periods through week 144 (about three years). In the CIMPASI trials, about 71% of patients originally randomized to the 200 mg dose still maintained 75% skin clearance at three years, and roughly 49% maintained 90% clearance.⁶ In the CIMPACT extension, patients who had been on Cimzia from the start maintained high response rates through the same period, and patients who had originally been on placebo saw their responses climb once they switched to active treatment.⁷

Real-world data echoes this. A study tracking patients outside the controlled trial setting found that about 77% achieved 75% clearance at 12 months, with roughly 57% hitting 90% clearance. The probability of patients still being on the drug at one year was about 85%, which signals that most people tolerate it well enough to keep going.⁸

Beyond skin, patients on Cimzia also reported sustained improvements in quality of life, work productivity, and daily activities over the three-year trial period.⁹

Where Cimzia Ranks Among Other Biologics

A large network meta-analysis comparing biologics for psoriasis grouped Cimzia with adalimumab, brodalumab, guselkumab, risankizumab, secukinumab, tildrakizumab, and ustekinumab as comparable in terms of high short-term efficacy and tolerability.¹⁰ That is a respectable cluster to be in, but the honest picture is more nuanced. Newer IL-17 and IL-23 inhibitors often achieve 90% or near-complete clearance in a larger share of patients than anti-TNF agents do, and they tend to get there faster.

Speed of onset is one area where Cimzia sits in the middle. A review of phase 3 trials found that half of patients on Cimzia 400 mg reached 75% clearance at about 7.5 weeks, compared to roughly 3.5 weeks for brodalumab, 4 weeks for ixekizumab, and 5 weeks for secukinumab. On the other hand, Cimzia was faster than etanercept, which took around 12.5 weeks to reach the same milestone.¹¹ If rapid visible clearance is a top priority and pregnancy is not a factor, an IL-17 inhibitor will typically outpace Cimzia.

The Pregnancy and Breastfeeding Advantage

This is where Cimzia has territory almost entirely to itself. Because it lacks the Fc region, the protein responsible for active antibody transport across the placenta, Cimzia does not cross to the fetus the way other biologics do. The CRIB study measured drug levels in newborns whose mothers had been taking Cimzia. Of 14 infants tested, 13 had no detectable drug in their blood at birth. The single infant with a measurable level had a vanishingly small amount, with an infant-to-mother concentration ratio of 0.0009.¹² In practical terms, the baby was essentially unexposed.

Breastfeeding data tells a similar story. The CRADLE study collected 137 breast milk samples from mothers on Cimzia. More than half had no measurable drug at all, and the estimated average daily infant dose was minuscule (the relative infant dose was a median of 0.15%, far below the 10% threshold generally considered concerning). Infant safety profiles were no different from those of unexposed babies the same age.¹³ A separate study measuring multiple biologics in breast milk found certolizumab in only 3 of 13 treated women, with a maximum concentration lower than that seen with infliximab, adalimumab, or ustekinumab.¹⁴

For someone with moderate-to-severe psoriasis who is pregnant, planning a pregnancy, or breastfeeding, this data genuinely changes the treatment conversation. With other anti-TNF agents, the standard practice has been to time the last dose well before the third trimester to avoid fetal drug exposure. Cimzia removes that constraint, which means disease control does not have to be sacrificed during a period when psoriasis flares can be physically and emotionally draining.

Psoriatic Arthritis and Dual Coverage

Many people with psoriasis eventually develop psoriatic arthritis, and choosing a biologic that addresses both is often preferable to stacking treatments. Cimzia is approved for psoriatic arthritis based largely on the RAPID-PsA trial, where roughly 58% of patients on the 200 mg dose achieved at least a 20% improvement in their joint symptoms by week 12, compared to about 24% on placebo. Improvements in joint disease started as early as the first week, and the drug also helped with the specific features of psoriatic arthritis that other measures miss: enthesitis (inflammation where tendons attach to bone), dactylitis (swollen “sausage” digits), and nail disease.¹⁵ These benefits were maintained over four years of follow-up, including in patients who had already tried and failed another anti-TNF drug.¹⁶

Patient-reported outcomes tell the same story. Fatigue, pain, physical function, and quality of life all improved significantly in both Cimzia dose groups compared to placebo, regardless of whether patients had been on a previous anti-TNF agent.¹⁷ Nail psoriasis, which is notoriously stubborn and often tracked separately, also responded to Cimzia across these studies.¹⁸

Safety, Infections, and Screening

The side-effect profile of Cimzia follows the general pattern of all anti-TNF drugs: an elevated risk of infections, including serious ones. A systematic review and meta-analysis across multiple inflammatory conditions found that patients on Cimzia had about a 28% higher rate of infections overall compared to control groups, and roughly double the rate of serious infections. Upper respiratory tract infections were the most commonly reported type. The overall rate of any adverse event was modestly higher in Cimzia-treated patients, and serious adverse events were about 50% more common.¹⁹ These numbers are not surprising for a TNF inhibitor and broadly mirror what is seen with adalimumab or infliximab.

Tuberculosis deserves special mention. All anti-TNF drugs carry a risk of reactivating latent TB, and screening before starting treatment is mandatory. Cimzia clinical trials tightened their TB screening protocols partway through, requiring a tuberculin skin test threshold of 5 mm or greater and nine months of preventive treatment for anyone who tested positive. Patients already enrolled when the stricter criteria were adopted were screened retroactively and treated if needed.²⁰ If you are starting Cimzia, expect a TB test and possibly a chest X-ray before your first dose. Hepatitis B screening is also standard practice before beginning any anti-TNF therapy.

Anti-Drug Antibodies and Loss of Response

One underappreciated factor with all biologics is that your immune system can develop antibodies against the drug itself, reducing its effectiveness. This happens with Cimzia, though the PEGylation may help keep rates relatively low. In a registry study of 310 patients with various inflammatory joint diseases, about 6% had detectable anti-drug antibodies after three months. Those who developed them had dramatically lower drug levels in their blood and were far less likely to respond to treatment — only about 1 in 11 of the antibody-positive patients was classified as a responder, compared to much higher response rates in those without antibodies.²¹ A 6% rate is lower than what some unPEGylated anti-TNF drugs see, but the clinical consequence when it does happen is substantial.

Whether You Need to Add Methotrexate

A common question with anti-TNF biologics is whether combining them with methotrexate improves results. In rheumatoid arthritis, the answer is often yes. In psoriatic arthritis and psoriasis, the evidence is less clear. A real-world cohort study found no difference in efficacy or safety between patients taking Cimzia alone and those combining it with methotrexate.²² A broader network meta-analysis of biologics in psoriatic arthritis reached the same conclusion: methotrexate did not appear to be necessary as background therapy for achieving joint response when a biologic was being used.²³ This matters practically because methotrexate comes with its own side effects, monitoring requirements, and alcohol restrictions. If it is not adding benefit, dropping it simplifies a patient’s life.

That said, some dermatologists still add low-dose methotrexate to reduce the chance of anti-drug antibody formation. Whether this trade-off makes sense depends on the individual, and the evidence for this strategy specifically with Cimzia is thin.

Cost and the Practical Calculus

Cimzia is not cheap, and on a pure cost-per-skin-clearance basis it does not look great compared to alternatives. One cost-effectiveness analysis found that the incremental cost per extra month a patient maintained 75% clearance was about $13,476 for Cimzia, compared to around $3,685 for brodalumab and $5,150 for tildrakizumab.²⁴ A separate analysis looking at cumulative clinical benefit over 16 weeks placed Cimzia’s performance at 90% clearance at about 20%, compared to 47% for ixekizumab.²⁵

These figures paint Cimzia as an expensive option for psoriasis alone, and if psoriasis clearance is your only consideration, several other biologics deliver more for less. But these analyses do not capture the full picture. If you have both psoriatic arthritis and skin disease and can treat both with a single drug, the value proposition shifts. And if you are a woman of childbearing age who wants a biologic compatible with pregnancy and breastfeeding, the cost comparison becomes almost irrelevant because no other anti-TNF offers the same placental transfer data. Cost-effectiveness models are useful, but they measure one dimension of a multi-dimensional decision.

Nail Psoriasis and Hard-to-Treat Sites

Nail involvement affects a large proportion of people with psoriasis and is among the most cosmetically distressing and treatment-resistant manifestations. Nails respond more slowly than skin plaques to any therapy, and many older treatments do little for them. A review of systemic treatments for nail psoriasis listed Cimzia among the biologics with demonstrated efficacy in recent trials, alongside adalimumab, secukinumab, ixekizumab, and others.²⁶ The RAPID-PsA trial specifically tracked nail outcomes and found sustained improvement over four years of treatment.²⁷ If nail disease is a dominant concern alongside joint symptoms, Cimzia is a reasonable option, though IL-17 inhibitors have generally shown stronger nail clearance rates in head-to-head comparisons.